SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS
Clinical trials for SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS trials appear
Sign up with your email to follow new studies for SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a diabetes drug help dialysis patients keep their kidneys working?
Disease control Recruiting nowThis study tests whether a daily 25 mg dose of empagliflozin (a diabetes drug) is safe and helps preserve remaining kidney function in 20 adults on peritoneal dialysis. Participants must still produce at least 250 mL of urine daily. The trial measures changes in kidney filtration…
Matched conditions: SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a diabetes drug shield Teens' kidneys?
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug already used in adults to protect kidneys, can reduce protein leakage in the urine of teenagers with mild chronic kidney disease. Two hundred adolescents aged 14 to 18 will receive either the drug or a placebo for six months. The goa…
Matched conditions: SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS
Phase: PHASE4 • Sponsor: Centenario Hospital Miguel Hidalgo • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC